Mariner’s Anika Therapeutics ANIK Stock Holding History

Mariner’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$380K	Buy	25,956 +14,973	+136%	+$222K	﹤0.01%	2649
2026 Q1	$159K	Buy	+10,983	New	+$127K	﹤0.01%	3225

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Mariner's ANIK Position: Q2 2026 in Review

Mariner increased its Anika Therapeutics (ANIK) stake by 136% in Q2 2026, buying an estimated $222K and bringing the position to 25,956 shares worth $380K. The position accounts for ﹤0.01% of the portfolio, ranked #2649.

Mariner first reported a position in ANIK in Q1 2026 and has held it in 2 quarters since. 134 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

Mariner held 25,956 shares of Anika Therapeutics worth $380K as of Q2 2026.
Mariner bought 14,973 Anika Therapeutics shares in Q2 2026, an estimated $222K.
Anika Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2649 holding.
Mariner first reported a position in Anika Therapeutics in Q1 2026 and has held it in 2 quarters since.
134 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.